Chemoradiation-induced changes in serum CEA and plasma TIMP-1 in patients with locally advanced rectal cancer.
BACKGROUND
Preoperative biomarkers serum CEA and plasma TIMP-1 have been shown to have prognostic and predictive value in patients with colorectal cancer. The aim of the present study was to evaluate the possible impact of chemoradiotherapy (CRT) on preoperative biomarker levels in patients with rectal cancer.


METHODS
Thirty-three patients with rectal cancer were prospectively included. The patients received CRT for 6-8 weeks. Blood samples were collected before CRT (pre-CRT) and preoperatively (post-CRT).


RESULTS
Median CEA was 3.5 (range 0.6-36.1) μg/l and 2.4 (range 0.0-10.2) μg/l (p=0.002) and median plasma TIMP-1 was 132.1 (range 77.8-342.7) μg/l and 140.0 (range 82.6-440.9) μg/l (p=0.04) in the pre- and post-CRT measurements, respectively.


CONCLUSIONS
CRT induced a significant decrease in serum CEA and increase in plasma TIMP-1 levels. Therefore, the preoperative biomarker levels may be affected by treatments received before blood sample collection. Translation of results of preoperative biomarkers needs to take such facts into consideration.
Department of Surgery, Hillerød Hospital, DK-3400 Hillerød, Denmark. bal@noh.regionh.dk
Bahir
B
Aldulaymi
Ib J
IJ
Christensen
György
G
Sölétormos
Per
P
Jess
Svend Erik
SE
Nielsen
Søren
S
Laurberg
Nils
N
Brünner
Hans J
HJ
Nielsen
D000230:Adenocarcinoma / Q000097:blood* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011300:Preoperative Care; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy; D015996:Survival Rate; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D019715:Tissue Inhibitor of Metalloproteinase-1